aTYR PHARMA INC — Director's Dealing 2022

Nov 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2022-11-21

Reporting Person: Shukla Sanjay (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-21	Common Stock	P	10000	$2.1405	Acquired	50798	Direct

Footnotes

F1: Represents weighted average price for the shares. The shares were purchased at prices ranging from $2.13 to $2.16 per share. The reporting
person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full
information regarding the number of shares purchased at each separate price